Article
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in…
medRxiv · 2020 · Ko M, Jeon S, Ryu W, Kim S.
Key facts
| Title | Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate |
|---|---|
| First author | Ko M, Jeon S, Ryu W, Kim S. |
| Journal | medRxiv |
| Published | May 12, 2020 |
| DOI | 10.1101/2020.05.12.090035 |
| Devices mentioned | 090035 |
At a glance
- 1–9 FDA submissions mentioned
- None Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1